CJC-1295 Cycles Explained: Where the Evidence Stops

CJC-1295 at a glance:

• Drug class: Long-acting GHRH analog (research peptide)
• Route: subcutaneous injection (research use)
• Typical frequency: varies; once weekly (DAC) or daily (no-DAC) in user protocols
• Half-life: approximately 6-8 days (DAC version); ~30 minutes (no-DAC version)

CJC-1295 doesn't have an FDA-approved dosing schedule. What gets called a "cycle" online comes from research methodology and online community consensus, not clinical evidence.

What "Cycle" Means in Peptide Discussions

In research-peptide and GHS communities, a "cycle" usually refers to a defined period of administration (often 8-12 weeks) followed by a break. The rationale draws on receptor desensitization theory and historical bodybuilding practice.

For CJC-1295: no formal cycling protocol has been studied in human RCTs. Online protocols are extrapolations, not evidence-based recommendations.

Published Research Dosing

Not FDA-approved. No officially established human dosing.

When peptides are studied in research, the doses come from animal-to-human translation, prior pharmacokinetic data, and trial designs that can't be assumed to apply to individual self-administration.

What Researchers Actually Do

In the published research literature on CJC-1295:

• Doses are typically expressed in mcg/kg or fixed mg amounts
• Administration routes match what was tested for safety
• Duration is bounded by the trial protocol (often 8-12 weeks)
• Outcome measurement is structured and pre-specified

These are not personal protocols; they're trial designs.

Why We Don't Publish Self-Administration Protocols

Three reasons:

1. Compound purity and identity are not verifiable for material from grey-market sources
2. Individual response to non-FDA-approved compounds is not characterized at the population level
3. Liability and safety realities make specific instructions inappropriate for an informational site

For CJC-1295 specifically, the evidence base is too thin to support specific guidance.

What to Do Instead

If you're researching CJC-1295 because of a specific health goal, the more productive path is usually:

• Identify the underlying issue (musculoskeletal, metabolic, etc.)
• Look at FDA-approved options that address it
• Talk to a clinician with relevant expertise
• Consider research-peptide options only as a last resort, with clear understanding of unknowns

Risks to Understand

• fluid retention
• carpal tunnel symptoms
• potential effect on glucose metabolism
• supply-chain contamination from unregulated suppliers

These are compound to the risks of unregulated supply (purity, contamination, dosing accuracy).

Bottom Line

CJC-1295 cycling discussions are popular online and thin in the evidence base. We'd rather be honest about that than fill the gap with confident-sounding speculation.

Frequently Asked Questions

Related Reading

• CJC-1295 101: A Plain-English Guide for 2026
• CJC-1295 Side Effects: The Complete List and How to Handle Them
• Does CJC-1295 Really Work? An Evidence-Based Results Review
• The Real CJC-1295 Price Tag in 2026 — With and Without Insurance
• The Honest Guide to MK-677: What Patients and Doctors Actually Say
• Is MK-677 Safe? An Honest Look at the Side-Effect Profile

Sources

• Teichman SL et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295. JCEM 2006;91:799.
• Stanley TL et al. Effects of Tesamorelin on Visceral Fat in HIV-Infected Patients With Lipodystrophy. NEJM 2010;363:2425.
• Nass R et al. Effects of an Oral Ghrelin Mimetic on Body Composition in Healthy Older Adults. Annals of Internal Medicine 2008;149:601.

This page is informational only and is not medical advice or a recommendation for self-administration of any compound.